S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
How does the Consumer Price Index affect the stock market?
A 'soft landing' or a recession? How each one might affect America's households and businesses
Closing prices for crude oil, gold and other commodities
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company

Applied DNA Sciences Stock Price, News & Analysis (NASDAQ:APDN)

$0.88
-0.20 (-18.50%)
(As of 12/8/2023 ET)
Compare
Today's Range
$0.88
$1.00
50-Day Range
$0.75
$1.14
52-Week Range
$0.75
$1.93
Volume
158,899 shs
Average Volume
28,252 shs
Market Capitalization
$12.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.50

Applied DNA Sciences MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
183.8% Upside
$2.50 Price Target
Short Interest
Healthy
2.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.21mentions of Applied DNA Sciences in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Industrial Products Sector

111th out of 176 stocks

Miscellaneous Business Services Industry

3rd out of 6 stocks


APDN stock logo

About Applied DNA Sciences Stock (NASDAQ:APDN)

Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. The company operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR)-based MDx testing services for the Monkeypox virus; and MDx test kits and related supplies, as well as validates pharmacogenetics (PGx) testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, leather, pharmaceuticals, nutraceuticals, and other products; SigNify IF portable DNA readers and SigNify consumable reagent test kits, which offers a front-line solution for supply chain integrity backed with forensic-level molecular tag authentication; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.

APDN Stock Price History

APDN Stock News Headlines

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Applied DNA Sciences Inc APDN
Earnings Preview: Applied DNA Sciences
ADT (ADT) Q2 Earnings and Revenues Miss Estimates
3 Penny Stocks to Buy Before the Breakout
See More Headlines
Receive APDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Applied DNA Sciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
12/07/2023
Today
12/09/2023
Next Earnings (Estimated)
2/08/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Industry
Miscellaneous business services
Sub-Industry
N/A
Current Symbol
NASDAQ:APDN
Employees
61
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.50
High Stock Price Target
$3.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+183.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-8,270,000.00
Pretax Margin
-43.79%

Debt

Sales & Book Value

Annual Sales
$13.37 million
Book Value
$1.08 per share

Miscellaneous

Free Float
12,726,000
Market Cap
$12.03 million
Optionable
Optionable
Beta
0.63
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. James A. Hayward Ph.D. (Age 69)
    Sc.D., Chairman, President & CEO
    Comp: $1.27M
  • Ms. Beth M. Jantzen CPA (Age 47)
    Chief Financial Officer
    Comp: $390k
  • Ms. Judith Murrah (Age 65)
    COO, Chief Information Officer & Secretary
    Comp: $438.75k
  • Mr. Sanjay M. Hurry
    Executive Director of Investor Relations & Corporate Communications
  • Mr. Clay Shorrock Esq. (Age 38)
    J.D., Chief Legal Officer & Executive Director of Business Development
  • Mr. Tony Benson
    Managing Director of EMEA
  • Mr. Joseph L. Magno
    Sales Consultant
  • Mr. Warren Pearlson
    Sales Consultant














APDN Stock Analysis - Frequently Asked Questions

Should I buy or sell Applied DNA Sciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Applied DNA Sciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" APDN shares.
View APDN analyst ratings
or view top-rated stocks.

What is Applied DNA Sciences' stock price target for 2024?

1 brokers have issued 12-month target prices for Applied DNA Sciences' stock. Their APDN share price targets range from $2.00 to $3.00. On average, they anticipate the company's share price to reach $2.50 in the next year. This suggests a possible upside of 183.8% from the stock's current price.
View analysts price targets for APDN
or view top-rated stocks among Wall Street analysts.

How have APDN shares performed in 2023?

Applied DNA Sciences' stock was trading at $1.66 at the start of the year. Since then, APDN stock has decreased by 46.9% and is now trading at $0.8810.
View the best growth stocks for 2023 here
.

When is Applied DNA Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 8th 2024.
View our APDN earnings forecast
.

How were Applied DNA Sciences' earnings last quarter?

Applied DNA Sciences, Inc. (NASDAQ:APDN) posted its quarterly earnings data on Thursday, December, 7th. The technology company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.01. The technology company had revenue of $0.78 million for the quarter, compared to analyst estimates of $1.60 million. Applied DNA Sciences had a negative net margin of 74.41% and a negative trailing twelve-month return on equity of 126.68%.

What is James A. Hayward's approval rating as Applied DNA Sciences' CEO?

2 employees have rated Applied DNA Sciences Chief Executive Officer James A. Hayward on Glassdoor.com. James A. Hayward has an approval rating of 100% among the company's employees. This puts James A. Hayward in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 100.0% of employees surveyed would recommend working at Applied DNA Sciences to a friend.

What other stocks do shareholders of Applied DNA Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Applied DNA Sciences investors own include Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), Ekso Bionics (EKSO), Micron Technology (MU), Arbutus Biopharma (ABUS), VBI Vaccines (VBIV), Gilead Sciences (GILD), Vaxart (VXRT), Sorrento Therapeutics (SRNE) and Intel (INTC).

Who are Applied DNA Sciences' major shareholders?

Applied DNA Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include AMH Equity Ltd (4.30%), Sabby Management LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Applied DNA Sciences?

Shares of APDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APDN) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -